Abstract: A formulation for a casting compound is provided that includes a base slip with a proportion between 18% and 36% by weight, quartz glass particles with a proportion between 40% and 70% by weight, and particles of an admixture having at least one multicomponent glass with a proportion between 10% and 40% by weight. The base slip contains water as dispersion medium with a content between 30% and 50% by weight and ultrafine Si0 2 particles colloidally distributed therein with a content between 50% and 70% by weight, and wherein the total water content in the formulation is 10% to 20% by weight. A composite material is also provided that has a largely crystalline Si0 2 matrix and particles of a multicomponent glass embedded therein.

Abstract: A formulation usable to produce plates and shaped bodies has a base slip, quartz glass particles and multicomponent glass particles that are crystallizable or at least partly crystallized. The base slip contains water as dispersion medium with a content between 30% and 50% by weight and ultrafine SiO2 particles distributed, preferably colloidally therein, with a proportion between 50% and 70% by weight. The proportion of quartz glass particles in the formulation is in the range from 40% to 70% by weight and the proportion the multicomponent glass particles in the formulation is in the range from 5% to 37% by weight. The formulation can be used in a composite material. Firing aids can be made from the composite material.

Abstract: An electronic unit, in particular for an electric fluid pump of a motor vehicle, having a functional element for holding electronics, and a heat sink arranged on the functional element, wherein the functional element and the heat sink are sealed from one another in fluid-tight fashion by means of a cured sealing compound of a liquid seal, and wherein the functional element has at least one ventilation opening, which is open in the course of a curing process for the sealing compound, and which, after the curing process, is sealed in fluid-tight fashion by means of a closure element.

Abstract: The present invention describes the combination of topically inhaled medicinal formulations comprising an anticholinergic component and a glucocorticosteroid component and its use in the symptomatic and prophylactic treatment of diseases of the respiratory tract, especially with an obstructive component or underlying inflammation like asthma and chronic obstructive pulmonary disease (COPD). It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the NOVOLIZER®.

Abstract: The invention relates to novel combinations based on anticholinergics, ?2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases.

Abstract: Pharmaceutical compositions comprising an anticholinergic and at least one leukotriene inhibitor for treatment of respiratory diseases, including allergic rhinitis, bronchial asthma, COPD and common cold, and methods of treatment.

Abstract: The invention relates to novel combinations based on anticholinergics, ?2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases.

Abstract: Novel combinations based on anticholinergics, ?2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases. A particular combination comprises R,R-glycopyrrolate, rolipram, and budesonide, or physiologically acceptable salts thereof, wherein dosage amounts are such that a synergistic therapeutic effect is achieved.

Abstract: The present invention describes a combination of an anticholinergic, such as R,R-glycopyrrolate, and a ? mimetic, such as tormoterol, for the treatment of respiratory diseases including airway inflammation or obstruction such as chronic obstructive pulmonary disease (COPD) and asthma.

Abstract: A system and method generate artistic multimedia representations of user-input texts, spoken or loaded narratives, theatrical scripts, or other linguistic corpus types, via a user interface, or batch interface, by classifying component words, and/or phrases into lexemes and/or parts of speech, and interpreting said classifications to construct playable structures. A database of natural language grammatical rules, a set of media objects, parameters, and rendering directives, and an algorithm facilitate the generation of sequential scenes from grammatical representations, convert user-input texts into playable structures of graphics, sounds, animations, and modifications, where playable structures may be combined to create a scene, or multiple scenes, and may be played in the order of occurrence in the input text as a sequential and timed multimedia representation of the input, and subsequently output, in real-time, or stored in memory for later output, via output devices such as a monitor and/or speakers.

Abstract: The invention relates to a method for cleaving cervimycin esters. An object of the invention to convert in a simple manner the cervimycin esters which are less active but formed in larger quantity into the highly active cervimycin K that occurs as a minor component in the preparation by fermentation, is achieved by preparing unesterified cervimycins from cervimycin esters with di- or monomethylated malonic acids, by ester cleavage effected by at least one esterolytic enzyme at temperatures of 20° C. to 75° C. and a pH of pH 5.0 to 10.0, preferably pH 6.0 to 9.0.

Abstract: The present invention describes the combination of topically inhaled medicinal formulations comprising an anticholinergic component and a glucocorticosteroid component and its use in the symptomatic and prophylactic treatment of diseases of the respiratory tract, especially with an obstructive component or underlying inflammation like asthma and chronic obstructive pulmonary disease (COPD). It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.

Abstract: The present invention provides, in one embodiment, a method for automatically analyzing an article of manufacture comprising the steps of a) providing a master model and a context model specification; b) creating a context model from the master model and the context model specification; c) translating the context model into an engineering analysis model compatible with an engineering analysis program; d) executing the engineering analysis program to generate a performance estimate form the engineering analysis model; and e) optionally modifying the master model to improve the performance estimate.

Abstract: The invention relates to an agent for treating skin diseases and/or functional disorders of the skin on the basis of different medicaments and/or auxiliary substances through promotion of penetration from topical formulations into the skin. According to the invention, the agent is composed of a hyaluronate lyase produced by microbial means and a medicament, preferably a hydrophilic medicament and/or auxiliary substances in different galenic formulations including colloidal carrier systems. The areas of application for the invention in human and veterinary medicament relate to the treatment, prophylaxis and/or metaphylaxis of skin diseases, functional disorders of the skin, the processes of skin ageing and dry skin conditions.

Abstract: The invention relates to an agent for the treatment, prophylaxis and metaphylaxis of functional and structural disorders of the skin caused by external factors. The agent contains a hyaluronic acid partially digested with a microbiological hyaluronate lyase. The hyaluronic acid fragment mixture is incorporated in different galenic formulations to which other hydrophilic and/or lipophilic active substances and/or auxiliary substances can be added. Fields of application of the invention in human and veterinary medicine relate to the treatment and/or the prophylaxis of skin damage caused by environmental factors including UV, dry skin conditions and skin ageing.

Abstract: An aluminum-based alloy having the following composition, % w/w: Lithium 1.5-1.9 Magnesium 4.1-6.0 Zinc 0.1-1.5 Zirconium 0.05-0.3  Manganese 0.01-0.8  Hydrogen 0.9 × 10−5-4.5 × 10−5 and at least one element selected from the following group: Beryllium 0.001-0.2  Yttrium 0.01-0.5 Scandium 0.01-0.3 Aluminum Remainder The process of heat treating the alloy includes the steps of quenching the alloy from a temperature of 400-500° C. in cold water or air, stretched-adjusting it to increase ductility up to 0 2 %, and a three stage heat treatment, in which in stage 1 the alloy is heated at 80-90° C. over the course of 3-12 h, in stage 2 it is heated at 110-185° C. over the course of 10-58 h, and in stage 3 it is heated at 90-110° C. for 14 h, or at a cooling rate of 2-8° C. C/h.

Abstract: A system and method of generating methane gas from organic material, e.g., animal waste. A mixture known to produce methane gas which may include animal waste and vegetation as desired, is treated, also as desired, with an inoculant and inserted into a plastic bag. The plastic bag is extended at one end beyond the portion filled with organic material to produce a collection space for collecting the gas. As the gas is generated, the gas migrates to the provided space and is released for collection and use as an energy source. An upper passage provided in the material enhances migration of the gas to the provided space. As desired, aeration conduits are provided in the material and upon depletion of the methane gas, the mixture may be treated for composting and used as fertilizer.

Abstract: An aluminum-based alloy having the following composition, % w/w: Lithium 1.5-1.9 Magnesium 4.1-6.0 Zinc 0.1-1.5 Zirconium 0.05-0.3 Manganese 0.01-0.8 Hydrogen 0.9 × 10−5-4.5 × 10−5 and at least one element selected from the following group: Beryllium 0.001-0.2 Yttrium 0.01-0.5 Scandium 0.01-0.3, Aluminum Remainder The process of heat treating the alloy includes the steps of quenching the alloy from a temperature of 400-500° C. in cold water or air, stretched-adjusting it to increase ductility up to 0 2 %, and a three stage heat treatment, in which in stage 1 the alloy is heated at 80-90° C. over the course of 3-12 h, in stage 2 it is heated at 110-185° C. over the course of 10-58 h, and in stage 3 it is heated at 90-110° C. for 14 h, or at a cooling rate of 2-80° C. C/h.